Cost-benefit analysis of Helicobacter pylori screening
Author
Abstract
Suggested Citation
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Peter Doubilet & Colin B. Begg & Milton C. Weinstein & Peter Braun & Barbara J. McNeil, 1985. "Probabilistic Sensitivity Analysis Using Monte Carlo Simulation," Medical Decision Making, , vol. 5(2), pages 157-177, June.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Dyfrig Hughes & Lesley Tilson & Michael Drummond, 2009. "Estimating Drug Costs in Economic Evaluations in Ireland and the UK," PharmacoEconomics, Springer, vol. 27(8), pages 635-643, August.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Jordan Amdahl & Jose Diaz & Arati Sharma & Jinhee Park & David Chandiwana & Thomas E Delea, 2017. "Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom," PLOS ONE, Public Library of Science, vol. 12(6), pages 1-18, June.
- Carus, Jana & Heuner, Maike & Paul, Maike & Schröder, Boris, 2017. "Which factors and processes drive the spatio-temporal dynamics of brackish marshes?—Insights from development and parameterisation of a mechanistic vegetation model," Ecological Modelling, Elsevier, vol. 363(C), pages 122-136.
- Nadia Yakhelef & Martine Audibert & Gabriella Ferlazzo & Joseph Sitienei & Steve Wanjala & Francis Varaine & Maryline Bonnet & Helena Huerga, 2020. "Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis," Post-Print halshs-03170014, HAL.
- David J. Vanness & W. Ray Kim, 2002. "Bayesian estimation, simulation and uncertainty analysis: the cost‐effectiveness of ganciclovir prophylaxis in liver transplantation," Health Economics, John Wiley & Sons, Ltd., vol. 11(6), pages 551-566, September.
- Karl Claxton & Elisabeth Fenwick & Mark J. Sculpher, 2012.
"Decision-making with Uncertainty: The Value of Information,"
Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 51,
Edward Elgar Publishing.
- Karl Claxton & Elizabeth Fenwick & Mark J. Sculpher, 2006. "Decision-making with Uncertainty: The Value of Information," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, chapter 48, Edward Elgar Publishing.
- Mehmet A. Ergun & Ali Hajjar & Oguzhan Alagoz & Murtuza Rampurwala, 2022. "Optimal breast cancer risk reduction policies tailored to personal risk level," Health Care Management Science, Springer, vol. 25(3), pages 363-388, September.
- Knoblauch, Theresa A.K. & Trutnevyte, Evelina, 2018. "Siting enhanced geothermal systems (EGS): Heat benefits versus induced seismicity risks from an investor and societal perspective," Energy, Elsevier, vol. 164(C), pages 1311-1325.
- Curtis P. Langlotz & Edward H. Shortliffe & Lawrence M. Fagan, 1988. "A Methodology for Generating Computer-based Explanations of Decision-theoretic Advice," Medical Decision Making, , vol. 8(4), pages 290-303, December.
- Akashdeep Singh Chauhan & Shankar Prinja & Sushmita Ghoshal & Roshan Verma & Arun S Oinam, 2018. "Cost of treatment for head and neck cancer in India," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
- Karl Claxton & Mark Sculpher & Chris McCabe & Andrew Briggs & Ron Akehurst & Martin Buxton & John Brazier & Tony O'Hagan, 2005. "Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra," Health Economics, John Wiley & Sons, Ltd., vol. 14(4), pages 339-347, April.
- James C. Felli & Gordon B. Hazen, 1999. "A Bayesian approach to sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 263-268, May.
- Joseph Gardiner & Andrew Hogan & Margaret Holmes-Rovner & David Rovner & Lawrence Griffith & Joel Kupersmith, 1995. "Confidence Intervals for Cost - Effectiveness Ratios," Medical Decision Making, , vol. 15(3), pages 254-263, August.
- M. Nuijten & T. Mittendorf & U. Persson, 2011. "Practical issues in handling data input and uncertainty in a budget impact analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 12(3), pages 231-241, June.
- Bas Groot Koerkamp & Milton C. Weinstein & Theo Stijnen & M.H. Heijenbrok-Kal & M.G. Myriam Hunink, 2010. "Uncertainty and Patient Heterogeneity in Medical Decision Models," Medical Decision Making, , vol. 30(2), pages 194-205, March.
- John Paul Ekwaru & Arto Ohinmaa & Bach Xuan Tran & Solmaz Setayeshgar & Jeffrey A Johnson & Paul J Veugelers, 2017. "Cost-effectiveness of a school-based health promotion program in Canada: A life-course modeling approach," PLOS ONE, Public Library of Science, vol. 12(5), pages 1-13, May.
- Lesong Conteh & Edith Patouillard & Margaret Kweku & Rosa Legood & Brian Greenwood & Daniel Chandramohan, 2010. "Cost Effectiveness of Seasonal Intermittent Preventive Treatment Using Amodiaquine & Artesunate or Sulphadoxine-Pyrimethamine in Ghanaian Children," PLOS ONE, Public Library of Science, vol. 5(8), pages 1-11, August.
- Gordon B. Hazen & Min Huang, 2006. "Parametric Sensitivity Analysis Using Large-Sample Approximate Bayesian Posterior Distributions," Decision Analysis, INFORMS, vol. 3(4), pages 208-219, December.
- A. E. Ades & Karl Claxton & Mark Sculpher, 2006. "Evidence synthesis, parameter correlation and probabilistic sensitivity analysis," Health Economics, John Wiley & Sons, Ltd., vol. 15(4), pages 373-381, April.
- Pedram Sendi & Huldrych F Günthard & Mathew Simcock & Bruno Ledergerber & Jörg Schüpbach & Manuel Battegay & for the Swiss HIV Cohort Study, 2007. "Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure," PLOS ONE, Public Library of Science, vol. 2(1), pages 1-8, January.
- Ya-Chen Shih & Josephine Mauskopf & Rohit Borker, 2007. "A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma," PharmacoEconomics, Springer, vol. 25(7), pages 577-590, July.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:70:y:2004:i:1:p:85-96. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.